Obesity Clinical Trial
Official title:
Genetic and Epigenetic Contribution to Increased Risk of T2D in the UAE
T2D is a global public health crisis and a threat to socioeconomic development of all
nations, particularly in developing countries. Countries in the Gulf region, including the
UAE, have some of the highest rates of T2D worldwide. The epidemic in the region has grown in
parallel with the worldwide rise in obesity, which is fuelled by rapid urbanization,
nutrition transition, and increasing sedentary lifestyles. Whether these unfavourable changes
in environmental risk factors can explain the increased risk of T2D in the region, or whether
the populations in the Gulf region are more genetically susceptible to disease is yet to be
investigated.
In this study, for the first time, the contribution of environmental, genetic, and epigenetic
factors towards the increased risk of T2D amongst the population of the UAE will be
investigated. This will be through, firstly, identifying environmental risk factors with
higher prevalence rates, and bigger effect sizes on T2D in the UAE in comparison to Europe.
Secondly, identifying genetic variants known to predict T2D in Europeans/other populations,
but with stronger association with T2D in Emiratis. Thirdly, identifying novel genetic
variants that are perhaps rare in Europeans/other populations, but confer increased risk for
T2D in the UAE. Lastly, candidate genes underlying T2D pathogenesis via epigenetic mechanisms
will be identified in Emiratis and Europeans. The end result is to identify the underlying
candidate markers and mechanisms involved in T2D pathogenesis, which can better explain
differences in magnitude of risk across populations.
The general aim of my research will be to investigate the contribution of environmental,
genetic, and epigenetic factors to the increased risk of T2D in the Emirati population
compared to Europeans. My specific aims will include:
1. Establish a cohort of Emirati T2D cases and controls to enable investigation of genetic
and environmental risk factors for T2D in the UAE.
2. Use the data collected to examine the contribution of adiposity, physical inactivity,
and dietary habits to the increased risk of T2D amongst the Emiratis compared to the
Europeans living in the UK.
3. Investigate whether known and novel genetic variants account for the high risk of T2D in
Emiratis.
4. Investigate DNA methylation profiles of subjects with T2D and non-diabetic controls in
Emiratis and Europeans, and identify the differences in methylation profiles between the
two populations.
5. Identify candidate methylation regions that are associated with, and could account for
the higher risk of T2D amongst Emiratis.
1. ESTABLISH A COHORT OF EMIRATI T2D CASES AND CONTROLS TO ENABLE INVESTIGATION OF GENETIC
AND ENVIRONMENTAL FACTORS FOR T2D IN THE UAE.
STUDY DESIGN: Case-control study SUBJECTS: 600 Emirati adults with T2D, and 600 age-sex
matched control free from T2D, recruited from Imperial College London Diabetes Centre (ICLDC)
based in Abu Dhabi, UAE. Recruitment started in April 2016. Participants include men and
women ≥18 years old. They are provided with a complete information letter about the study,
and are asked to sign a written consent to be included in the study.
METHODS: Participants will undergo health examination, which will be conducted by nurses and
interviewers at the ICLDC. Examinations will include a brief medical history, anthropometric
measures including weight, height, waist and hip circumferences, and blood pressure. Blood
samples will be collected after an 8-hour fast for biochemical analysis, which includes
measuring glucose, insulin, HDL and total cholesterol, and triglycerides levels. Diabetes
will be defined using 1999 WHO criteria. Obesity will be assessed by BMI, where subjects will
be classified as obese if BMI ≥30 kg/m2 and overweight if 25 kg/m2 ≤ BMI < 30 kg/m2.
Additionally, participants will be asked to fill a physical activity questionnaire to assess
their activity at work, transport, and recreational times during a typical week. A subset of
200 participants, 100 free from T2D and 100 with T2D, will be asked to wear Actigraph
activity monitors that will measure their physical activity levels for 7 days. These
participants will also be asked to fill out a food frequency questionnaire to assess their
dietary habits.
ANALYSIS: Data will be examined for completeness, consistency, and response rates and for
evidence of responder bias. I will carry out descriptive analyses to define the age and
sex-specific prevalence of conventional risk factors for T2D amongst Emiratis, and their
relationship with T2D in this population.
JUSTIFICATION: This project was planned to start in March 2016; however, due to lack of
funding, and delays in college enrolment, I was not able to continue with my analyses. During
April 2016 - Feb 2017, I have completed recruiting 1000 Emirati subjects; 500 with T2D and
500 free from diabetes. I will now continue recruiting 200 more subjects for physical
activity monitoring and dietary habits data collection.
2. EXAMINE THE CONTRIBUTION OF ENVIRONMENTAL RISK FACTORS TO THE INCREASED RISK OF T2D IN THE
UAE.
STUDY DESIGN: Case-control study SUBJECTS: The cohort of Emirati T2D cases and controls
collected (specific aim 1), as well as ~5,000 Europeans.
ANALYSIS: Assess differences in BMI, waist and hip circumference, physical activity levels,
and dietary intake among Emiratis and Europeans who are free from diabetes. This will allow
me to identify whether differences in the prevalence rates of T2D in Emirati and European
subjects reported in the literature is paralleled with different rates of environmental risk
factors. Furthermore, the strength of the association of environmental risk factors with T2D
will be assessed using logistic regression. Odds ratios (OR, Confidence Interval (CI) 95%) of
age, BMI, waist-to-hip ratio (WHR), physical inactivity, and dietary intake will be
calculated amongst Emiratis and compared to Europeans. This will assess whether environmental
risk factors can explain the difference in T2D magnitude of risk between the two populations.
3. CARRY OUT GENOME-WIDE ASSOCIATION ANALYSIS TO IDENTIFY NOVEL AND KNOWN GENETIC LOCI
INFLUENCING, AND CONTRIBUTING TO INCREASED RISK OF T2D IN THE UAE.
STUDY DESIGN: Case-control study. SUBJECTS: The cohort of Emirati T2D cases and controls
collected (specific aim 1), as well as ~5,000 Europeans.
METHODS: Whole blood samples will be collected from participants after an 8-hour fast for DNA
extraction and genotyping. DNA will be extracted using PureLinkTM Genomic DNA extraction kit
(Invitrogen, Life Technologies), following manufacturer's instructions. Genotyping will be
carried out on the Illumina Infinium II SNP genotyping array, which scales genotyping of up
to 500,000 SNP loci. Amplified and fragmented DNA samples will be applied to BeadChips, where
they anneal to locus-specific 50-mers (covalently linked to one of over 500,000 bead types).
One bead type corresponds to each allele per SNP locus. Allelic specificity is conferred by
enzymatic base extension, and subsequently identified by measuring beads' fluorescence
intensities.
ANALYSIS: Identify variants with higher allele frequencies among Emiratis compared to
Europeans. Allele frequencies will be compared between Emirati subjects with T2D and healthy
controls to identify known and novel genetic loci that are associated with T2D in the UAE.
The strength of association of genetic variants with T2D will be analysed with logistic
regression under an additive genetic model to estimate effect sizes (ORs, CI 95%). Effect
sizes will be compared to data from Europeans to assess whether identified genetic variants
can explain part of the increased risk of T2D among Emiratis.
In addition, I will test SNPs for association with fasting glucose levels, fasting insulin
levels, triglycerides levels, insulin sensitivity or β-cell function, under an additive
genetic model, and effect sizes will be compared to data from Europeans. Furthermore, the
combined effect of genetic loci influencing similar T2D- related phenotypic traits will be
tested across the two populations. This will be through evaluating the effect of carrying
increasing number of risk alleles on a T2D intermediate phenotype in Emiratis compared to
Europeans.
JUSTIFICATION: Due to recruitment and funding constraints, GWA analyses will be carried out
in only 600 T2D cases and 600 controls free from diabetes. With this sample size, I will be
able to identify Emirati-specific genetic risk variants that have 10% minor allele frequency
and an effect size of 1.3, with 80% power. This fulfils our aim of identifying
Emirati-specific variants with possible clinical relevance. Table 1 summarizes the sample
size required for a range of minor allele frequencies and odds ratios in a case-control study
design.
4. INVESTIGATE DIFFERENCES IN DNA METHYLATION PROFILES BETWEEN EMIRATIS AND EUROPEANS, AND
IDENTIFY CANDIDATE METHYLATION REGIONS THAT CAN ACCOUNT FOR THE HIGHER RISK OF T2D AMONG
EMIRATIS AND UNDERLIE DISEASE PATHOGENESIS.
STUDY DESIGN: Case-control study. SUBJECTS: A subset of the cohort collected (specific aim
1), including 100 Emirati T2D cases, 100 insulin resistant controls, and 100 insulin
sensitive controls. In addition to 100 European adults with T2D, 100 insulin resistant
controls, and 100 insulin sensitive controls. All subjects included will be age and sex
matched.
METHODS: Whole blood samples will be collected from participants. DNA will be extracted from
isolated blood leukocytes for DNA methylation assays. Genomic DNA will be treated by
bisulphite conversion, and bisulphite converted DNA will be analysed using Illumina Infinium
Human Methylation 450K BeadChip Array technology. The BeadChip interrogates 485,577 cytosine
positions in the human genome; the majority are CpG (cytosine-guanine nucleotide pairs)
dinucleotides, with sites located within known gene regions, including promoter, gene body,
intergenic, and untranslated regions.
ANALYSIS: For a given CpG site, methylation status is defined by a beta value, which is
calculated as the intensity of methylated channel divided by total intensity. Methylation for
genomic regions will be calculated as the mean beta for all probes located within the region.
Identification of differentially methylated regions (DMRs) will be performed using the probe
lasso method implemented in the R package ChAMP. DNA methylation profiles of Emiratis and
Europeans free from diabetes will be compared to identify differences in methylation profiles
across populations. DNA methylation profiles in Emiratis and Europeans with T2D and/or
insulin resistance will be compared to that of insulin sensitive controls to identify DMRs
associated with T2D and/or insulin resistance in each population. The strength of association
of DMRs with T2D and/or insulin resistance will be analysed with logistic regression to
estimate effect sizes (ORs, CI 95%). Effect sizes will be compared across the two populations
to assess whether identified DMRs can explain part of the increased risk of T2D among
Emiratis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |